IBRX
Immunitybio Inc
8.60$
-7.1%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 5,591.5% | 3,283.5% | 11,387.5% | 420.8% | 2.5% | 54.8% | 0.4% | 0.5% | 12.9% | 11.1% | 0.5% | 0.6% | 5.4% | |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.6% | 99.5% | 87.1% | 88.9% | 99.5% | 99.4% | 94.6% | |
| 59,026.8% | 37,073.4% | 133,377.5% | 4,883.4% | 826.1% | 466.4% | 292.0% | 209.0% | 158.2% | 158.8% | 146.5% | 112.6% | 141.1% | |
| 38,800.0% | 23,820.1% | 104,712.5% | 4,704.0% | 588.2% | 552.6% | 197.7% | 160.2% | 113.2% | 101.2% | 103.5% | 101.1% | 104.1% | |
| 97,826.8% | 61,530.9% | 238,090.0% | 9,587.4% | 1,414.3% | 1,019.0% | 489.7% | 369.2% | 260.6% | 257.9% | 257.3% | 219.8% | 246.5% | |
| -97,726.8% | -61,430.9% | -237,990.0% | -9,487.4% | -1,314.3% | -919.0% | -390.1% | -269.8% | -173.5% | -169.0% | -157.9% | -120.4% | -151.9% | |
| 42,708.5% | 23,112.2% | 93,717.5% | 3,726.7% | 659.1% | 197.4% | 174.8% | 109.3% | 86.0% | 71.0% | 64.4% | 0.0% | 50.2% | |
| -116,636.6% | -167,952.5% | -335,325.0% | -12,854.3% | -1,404.4% | -783.6% | -786.5% | -349.3% | -209.9% | -162.2% | -1,431.5% | -449.6% | -598.7% | |
| -5,591.5% | -28.8% | -52.5% | -420.8% | – | 0.2% | -1.4% | 1.0% | -0.1% | -0.4% | 0.0% | – | – | |
| -116,563.4% | -167,907.9% | -335,272.5% | -12,852.3% | -1,404.0% | -783.4% | -784.9% | -350.3% | -209.8% | -161.8% | -1,431.4% | -449.6% | -598.6% | |
| -68,395.1% | -141,556.8% | -244,092.5% | -8,706.7% | -672.6% | -531.3% | -588.5% | -225.3% | -111.6% | -81.1% | -1,357.2% | -432.4% | -535.8% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.